Large-scale molecular dynamics of a G protein-coupled receptor, the human 5-HT4 serotonin receptor, in a lipid bilayer

Journal of Molecular Structure: THEOCHEM

Volumn 817, Issue 1-3, 2007, Pages 19-26

  Rivail, L ^a   Chipot, C ^b   Maigret, B ^b   Bestel, I ^a   Sicsic, S ^a   Tarek, M ^b  

^a UNIVERSITÉ PARIS SUD   (France)

^b NANCY UNIVERSITÉ   (France)

Author keywords

5HT4 receptor; Free energy calculations; GPCR; Molecular dynamic; Molecular model; Protein ligand interaction

Indexed keywords

EID: 34547659996     PISSN: 01661280     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.theochem.2007.04.012     Document Type: Article

References (74)

1. 4 receptor binding site: exploration of a hydrophobic pocket. Br. J. Pharmacol. 143 3 (2004) 361-370
2. 4. J. Chem. Inform. Comput. Sci. (2001) A-F
3. Lopez-Rodriguez M.L., et al. Comparative receptor mapping of serotoninergic 5-HT3 and 5-HT4 binding sites. J. Comput. Aided Mol. Des. 11 6 (1997) 589-599
4. Dumuis A., Sebben M., and Bockaert J. The gastrointestinal prokinetic benzamide derivatives are agonists at the non-classical 5-HT receptor (5-HT4) positively coupled to adenylate cyclase in neurons. Naunyn Schmiedebergs Arch. Pharmacol. 340 4 (1989) 403-410
5. Hoyer D., et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol. Rev. 46 2 (1994) 157-203
6. Blondel O., et al. Cloning, expression, and pharmacology of four human 5-hydroxytryptamine 4 receptor isoforms produced by alternative splicing in the carboxyl terminus. J. Neurochem. 70 6 (1998) 2252-2261
7. Claeysen S., et al. Novel brain-specific 5-HT4 receptor splice variants show marked constitutive activity: role of the C-terminal intracellular domain. Mol. Pharmacol. 55 5 (1999) 910-920
8. Eglen R.M., et al. Characterization of 5-HT3 and `atypical' 5-HT receptors mediating guinea-pig ileal contractions in vitro. Br. J. Pharmacol. 101 3 (1990) 513-520
9. 4 receptors. FASEB J. 10 (1996) 1398-1407
10. Bouras E.P., et al. Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut 44 5 (1999) 682-686
11. Kaumann A.J. Do human atrial 5-HT4 receptors mediate arrhythmias?. Trends Pharmacol. Sci. 15 12 (1994) 451-455
12. Marchetti-Gauthier E., et al. BIMU1 increases associative memory in rats by activating 5-HT4 receptors. Neuropharmacology 36 4-5 (1997) 697-706
13. Robert S.J., et al. The human serotonin 5-HT4 receptor regulates secretion of non-amyloidogenic precursor protein. J. Biol. Chem. 276 48 (2001) 44881-44888
14. Langlois M., and Fischmeister R. 5-HT(4) receptor ligands: applications and new prospects. J. Med. Chem. 46 3 (2003) 319-344
15. Takeda S., et al. Identification of G protein-coupled receptor genes from human genome sequence. FEBS Lett. 520 (2002) 97-101
16. Wise A., Gearing K., and Rees S. Target validation of G-protein coupled receptors. Drug Discov. Today 7 (2002) 235-246
17. Henderson R., et al. Model for the structure of bacteriorhodopsin based on high-resolution electron cryo-microscopy. J. Mol. Biol. 213 4 (1990) 899-929
18. Palczewski K., et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289 5480 (2000) 739-745
19. Ballesteros J.A., Shi L., and Javitch J.A. Structural mimicry in G protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors. Mol. Pharmacol. 60 1 (2001) 1-19
20. Lu Z.L., Saldanha J.W., and Hulme E.C. Seven-transmembrane receptors: crystals clarify. Trends Pharmacol. Sci. 23 3 (2002) 140-146
21. 4 receptor. Mol. Pharmacol. 62 1 (2002) 38-47
22. Manivet P., et al. The serotonin binding site of human and murine 5-HT2B receptors: molecular modeling and site-directed mutagenesis. J. Biol. Chem. 277 19 (2002) 17170-17178
23. Archer E., et al. Rhodopsine crystal : new template yielding realistic models of G-protein receptor?. Trends Pharmacol. Sci. 24 (2002)
24. Buchheit K.H., et al. The serotonin 5-HT4 receptor. 1. Design of a new class of agonists and receptor map of the agonist recognition site. J. Med. Chem. 38 13 (1995) 2326-2330
25. Gaster L.M., and King F.D. Serotonin 5-HT3 and 5-HT4 receptor antagonists. Med. Res. Rev. 17 2 (1997) 163-214
26. Iskander M.N., Coupar I.M., and Winkler D.A. Investigation of 5-HT4 agonist activities using molecular field analysis. J. Chem. Soc., Perkin Trans. 2 (1999) 153-158
27. Mialet J., et al. Exploration of the ligand binding site of the human 5-HT(4s) receptor by site-directed mutagenesis and molecular modeling. Br. J. Pharmacol. 130 3 (2000) 527-538
28. 4 receptor agonist. Br. J. Pharmacol. 114 (1995) 382P
29. Mialet J., et al. Pharmacological characterization of the human 5-HT(4(d)) receptor splice variant stably expressed in Chinese hamster ovary cells. Br. J. Pharmacol. 131 4 (2000) 827-835
30. Mialet J., et al. Isolation of the serotoninergic 5-HT4(e) receptor from human heart and comparative analysis of its pharmacological profile in C6-glial and CHO cell lines. Br. J. Pharmacol. 129 4 (2000) 771-781
31. MacKerell Jr. A.D., et al. All-atom empirical potential for molecular modeling and dynamics Studies of proteins. J. Phys. Chem. B 102 (1998) 3586-3616
32. Angyan J.G., et al. OPEP: a tool for the optimal partitioning of electric properties. J. Comput. Chem. 24 8 (2003) 997-1008
33. Frisch, et al., GAUSSIAN 98 Revision A.7. 1999, Gaussian Inc.: Pittsburgh, PA.
34. De Groot B.L., and Grubmüller H. Water permeation across biological membranes: mechanism and dynamics of aquaporin-1 and GlpF. Science 294 (2001) 2353-2357
35. Tarek M., Maigret B., and Chipot C. Molecular dynamics investigation of an oriented cyclic peptide nanotube in DMPC bilayers. Biophys. J. 85 (2003) 2287-2298
36. Kale L., et al. NAMD2: greater scalability for parallel molecular dynamics. J. Comput. Phys. 151 (1999) 283-312
37. Izaguirre J.A., Reich S., and Skeel R. Longer time steps for molecular dynamics. J. Chem. Phys. 110 20 (1999) 9853-9864
38. Jesus A., et al. Langevin stabilization of molecular dynamics. J. Chem. Phys. 114 5 (2001) 2090-2098
39. Darden T., York D., and Pedersen L.G. Particle mesh Ewald: an N log(N) method for Ewald sums in large systems. J. Chem. Phys. 98 12 (1993) 10089-10092
40. Essmann U., et al. A smooth particle mesh Ewald method. J. Chem. Phys. 103 9 (1995) 8577-8593
41. Ryckaert J.P., Ciccotti G., and Berendsen H.J.C. Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-Alkanes. J. Comput. Phys. 23 (1977) 327-341
42. Andersen H.C. RATTLE: a velocity version of the SHAKE algorithm for molecular dynamics. J. Comput. Chem. 52 (1983) 24-34
43. Gao J., et al. Hidden thermodynamics of mutants proteins: a molecular dynamics analysis. Science 244 (1989) 1069-1072
44. Joubert L., et al. A 5-HT4 receptor transmembrane network implicated in the activity of inverse agonists but not agonists. J. Biol. Chem. 277 28 (2002) 25502-25511
45. Gether U. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr. Rev. 21 1 (2000) 90-113
46. Frishman D., and Argos P. Knowledge-based protein secondary structure assignment. Proteins 23 4 (1995) 566-579
47. Ho B.Y., et al. The role of conserved aspartate and serine residues in ligand binding and in function of the 5-HT1A receptor: a site-directed mutation study. FEBS Lett. 312 2-3 (1992) 259-262
48. 1Dβ receptors. Eur. J. Med. Chem. 32 (1997) 59-69
49. 2C receptor interaction. Eur. J. Pharmacol. 306 (1996) 195-210
50. Cavalli A., et al. Amino acids of the alpha1B-adrenergic receptor involved in agonist binding: differences in docking catecholamines to receptor subtypes. FEBS Lett. 399 1-2 (1996) 9-13
51. Wang C.D., Buck M.A., and Fraser C.M. Site-directed mutagenesis of alpha 2A-adrenergic receptors: identification of amino acids involved in ligand binding and receptor activation by agonists. Mol. Pharmacol. 40 2 (1991) 168-179
52. Strader C.D., et al. Identification of residues required for ligand binding to the beta-adrenergic receptor. Proc. Natl. Acad. Sci. USA 84 13 (1987) 4384-4388
53. Strader C.D., et al. Conserved aspartic acid residues 79 and 113 of the beta-adrenergic receptor have different roles in receptor function. J. Biol. Chem. 263 21 (1988) 10267-10271
54. Wang C.D., Gallaher T.K., and Shih J.C. Site-directed mutagenesis of the serotonin 5-hydroxytrypamine2 receptor: identification of amino acids necessary for ligand binding and receptor activation. Mol. Pharmacol. 43 6 (1993) 931-940
55. Boess F.G., Monsma Jr. F.J., and Sleight A.J. Identification of residues in transmembrane regions III and VI that contribute to the ligand binding site of the serotonin 5-HT6 receptor. J. Neurochem. 71 5 (1998) 2169-2177
56. Javitch J.A., et al. Mapping the binding-site crevice of the dopamine D2 receptor by the substituted-cysteine accessibility method. Neuron 14 4 (1995) 825-831
57. Fraser C.M., et al. Site-directed mutagenesis of m1 muscarinic acetylcholine receptors: conserved aspartic acids play important roles in receptor function. Mol. Pharmacol. 36 6 (1989) 840-847
58. Roth B.L., et al. Identification of conserved aromatic residues essential for agonist binding and second messenger production at 5-hydroxytryptamine2A receptors. Mol. Pharmacol. 52 2 (1997) 259-266
59. Cho W., et al. Hydrophobic residues of the D2 dopamine receptor are important for binding and signal transduction. J. Neurochem. 65 (1995) 2105
60. Yang D., et al. New esters of 4-amino-5-chloro-2-methoxybenzoic acid as potent agonists and antagonists for 5-HT4 receptors. J. Med. Chem. 40 4 (1997) 608-621
61. Filipek S., et al. The crystallographic model of rhodopsin and its use in studies of other G-protein coupled receptors. Ann. Rev. Biophys. Biomol. Struct. 32 (2003) 375-397
62. Ballesteros J., and Palczewski K. G protein-coupled receptor drug discovery: implications from the crystal structure of rhodopsin. Curr. Opin. Drug Discov. Dev. 4 5 (2001) 561-574
63. Huber T., et al. Membrane model for the G-protein coupled receptor rhodopsin: hydrophobic interface and dynamical structure. Biophys. J. 86 (2004) 2078-2100
64. Trent J.O., et al. Lipid bilayer simulations of CXCR4 with inverse agonists and weak partial agonists. J. Biol. Chem. 278 (2003) 47136-47144
65. Zhang Y., et al. Homology modeling and molecular dynamics simulations of the mu opioid receptor in a membrane-aqueous system. Chem. Bio. Chem. 6 (2005) 1-7
66. Aburi M., and Smith P.E. Modeling and simulation of delta opioid receptor. Protein Sci. 13 (2004) 1997-2000
67. Hénin J., et al. Probing a model of a GPCR/ligand complex in an explicit membrane enviroment. The human cholecyctokinin-1 receptor. Biophys. J. (2005)
68. Rogalska E., et al. Self-assembly of chlorophenol in water. PNAS 96 12 (1999) 6577-6580
69. Simonson T., Archontis G., and Karplus M. Free enregy simulations come of age: protein-ligand recognition. Acc. Chem. Res. 35 (2002) 430-437
70. Chipot C., and Pearlman D.A. Free energy calculations. The long and winding gilded road. Mol. Sim. 28 (2002) 1-12
71. Berthouze M., et al. Constitutive dimerization of human serotonin 5-HT4 receptors in living cells. FEBS Lett. 579 14 (2005) 2973-2980
72. Bouvier M. Oligomerization of G-protein-coupled transmitter receptors. Nat. Rev. Neurosci. 2 4 (2001) 274-286
73. Breitwieser G.E. G protein-coupled receptor oligomerization: implications for G protein activation and cell signaling. Circ. Res. 94 1 (2004) 17-27
74. Soulier J.L., et al. Design and synthesis of specific probes for human 5-HT4 receptor dimerization studies. J. Med. Chem. 48 20 (2005) 6220-6228